A common genetic variant in FCGR3A-V158F and risk of Kaposi sarcoma herpesvirus infection and classic Kaposi sarcoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 3, 2005, Pages 633-637

  Brown, Elizabeth E ^a,b   Fallin, M Daniele ^b   Goedert, James J ^a   Chen, Renee ^a   Whitby, Denise ^c   Foster, Charles B ^b   Lauria, Carmela ^d   Alberg, Anthony J ^b   Messina, Angelo ^e   Montella, Mauizio ^f   Rezza, Giovanni ^g   Vitale, Francesco ^h   Chanock, Stephen J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Lega Italiana per la Lotta Contro i Tumori Sez Ragusa   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^h UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; DNA; LATENT NUCLEAR ANTIGEN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALLELE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FCGR3A GENE; FEMALE; GENE; GENE DOSAGE; GENE SEQUENCE; GENETIC RISK; GENETIC VARIABILITY; HERPES; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE TEST; ITALY; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SEQUENCE ANALYSIS; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; ITALY; MALE; MIDDLE AGED; ODDS RATIO; RECEPTORS, IGG; RISK FACTORS; SARCOMA, KAPOSI; VARIATION (GENETICS);

EID: 20144388186     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0598     Document Type: Article

References (50)

1. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9.
2. Geddes M, Franceschi S, Barchielli A, et al. Kaposi's sarcoma in Italy before and after the AIDS epidemic. Br J Cancer 1994;69:333-6.
3. Touloumi G, Hatzakis A, Potouridou I, et al. The role of immunosuppression and immune-activation in classic Kaposi's sarcoma. Int J Cancer 1999;82:817-21.
4. Biron CA. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol 1997;9:24-34.
5. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975;16:230-9.
6. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975;5:112-7.
7. Sirianni MC, Vincenzi L, Topino S, et al. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol 2002;32:2711-20.
8. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989;320:1731-5.
9. de Vries E, Koene HR, Vossen JM, et al. Identification of an unusual Fc γ receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood 1996;88:3022-7.
10. Strayer DR, Carter WA, Mayberry SD, Pequignot E, Brodsky I. Low natural cytotoxicity of peripheral blood mononuclear cells in individuals with high familial incidences of cancer. Cancer Res 1984;44:370-4.
11. Pross HF, Sterns E, MacGillis DR. Natural killer cell activity in women at "high risk" for breast cancer, with and without benign breast syndrome. Int J Cancer 1984;34:303-8.
12. Braun DP, Harris JE. Abnormal monocyte function in patients with Kaposi's sarcoma. Cancer 1986;57:1501-6.
13. Friedman-Birnbaum R, Weltfriend S, Pollack S. Classic Kaposi's sarcoma; T-lymphocyte subsets, T4/T8 ratio, and NK cell activity. J Am Acad Dermatol 1991;24;937-40.
14. van de Winkel JG, Capel PJ. Human IgG Fc receptor heterogeneity; molecular aspects and clinical implications. Immunol Today 1993;14:215-21.
15. Rascu A, Repp R, Westerdaal NA, Kalden JR, van de Winkel JG. Clinical relevance of Fc γ receptor polymorphisms, Ann N Y Acad Sci 1997;815:282-95.
16. Ravetch JV, Perussia B. Alternative membrane forms of Fc γ RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med 1989;170:481-97.
17. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc γRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc γRIIIa, independently of the Fc γRIIIa-48L/R/H phenotype. Blood 1997;90:1109-14.
18. Vance BA, Huizinga TW, Wardwell K, Guyre PM, Binding of monomeric human IgG defines an expression polymorphism of Fc γ RIII on large granular lymphocyte/natural killer cells. J Immunol 1993;151:6429-39.
19. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-70.
20. Koene HR, Kleijer M, Swaak AJ, et al. The Fc γRIIIA-158F allele is a risk factor for systemic lupus erythematosus. Arthritis Rheum 1998;41:1813-8.
21. Muller Kobold AC, Zijlstra JG, Koene HR, de Haas M, Kallenberg CG, Tervaert JW. Levels of soluble Fc γRIII correlate with disease severity in sepsis. Clin Exp Immunol 1998;114:220-7.
22. van der Pol WL, Huizinga TW, Vidarsson G, et al. Relevance of Fcγ receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 2001;184;1548-55.
23. Meisel P, Carlsson LE, Sawaf H, Fanghaenel J, Greinacher A, Kocher T. Polymorphisms of Fc γ-receptors RIIa, RIIIa, and RIIIb in patients with adult periodontal diseases. Genes Immun 2001;2:258-62.
24. Lehrnbecher TL, Foster CB, Zhu S, et al. Variant genotypes of FcγRIIIA influence the development of Kaposi's sarcoma in HIV-infected men. Blood 2000;95:2386-90.
25. Vitale F, Briffa DV, Whitby D, et al. Kaposi's sarcoma herpes virus and Kaposi's sarcoma in the elderly populations of 3 Mediterranean islands. Int J Cancer 2001;91:588-91.
26. Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. J Natl Cancer Inst 2002;94:1712-8.
27. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995;346:799-802.
28. Biggar RJ, Whitby D, Marshall V, Linhares AC, Black F. Human herpesvirus 8 in Brazilian Amerindians: a hyperendemic population with a new subtype. J Infect Dis 2000;181:1562-8.
29. de Sanjose S, Marshall V, Sola J, et al. Prevalence of Kaposi's sarcoma-associated herpesvirus infection in sex workers and women from the general population in Spain. Int J Cancer 2002;98:155-8.
30. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000;18:2593-602.
31. Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3 real time PCR assay. J Virol Methods 2001;91:109-17.
32. Lehrnbecher T, Foster CB, Zhu S, et al. Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations. Blood 1999;94:4220-32.
33. Hosmer D, Lemenshaw S. Applied logistic regression. New York: Wiley; 1989.
34. Valentin A, Rosati M, Patenaude DJ, et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2002;99:7015-20.
35. Bijlsma JW, Cutolo M, Masi AT, Chikanza IC. The neuroendocrine immune basis of rheumatic diseases. Immunol Today 1999;20:298-301.
36. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol 2001;2:777-80.
37. Schuurs AH, Verheul HA. Effects of gender and sex steroids on the immune response. J Steroid Biochem 1990;35:157-72.
38. Klein SL. The effects of hormones on sex differences in infection: from genes to behavior. Neurosci Biobehav Rev 2000;24:627-38.
39. Carr R, Huizinga TW, Kleijer M, Davies JM. Changes in plasma FcRIII demonstrate increasing receptor production during late pregnancy and after preterm birth. Pediatr Res 1992;32:505-8.
40. Koyama M, Saji F, Kameda T, et al. Differential mRNA expression of three distinct classes of Fc γ receptor at the feto-maternal interface. J Reprod Immunol 1991;20:103-13.
41. Heinzmann A, Mao XQ, Akaiwa M, et al. Generic variants of IL-13 signalling and human asthma and atopy. Hum Mol Genet 2000;9:549-59.
42. Rhodes K, Scott A, Markham RL, Monk-Jones ME. Immunological sex differences. A study of patients with rheumatoid arthritis, their relatives, and controls. Ann Rheum Dis 1969;28:104-20.
43. Cottoni F, De Marco R, Montesu MA. Classical Kaposi's sarcoma in northeast Sardinia: an overview from 1977 to 1991. Br J Cancer 1996;73:1132-3.
44. Perna AM, Bonura F, Vitale F, et al. Antibodies to human herpes virus type 8 (HHV8) in general population and in individuals at risk for sexually transmitted diseases in Western Sicily. Int J Epidemiol 2000;29:175-9.
45. Atzori L, Fadda D, Ferreli C, et al. Classic Kaposi's sarcoma in southern Sardinia, Italy. Br J Cancer 2004;91:1261-2.
46. Maiorana A, Luppi M, Barozzi P, Collina G, Fano RA, Torelli G. Detection of human herpes virus type 8 DNA sequences as a valuable aid in the differential diagnosis of Kaposi's sarcoma. Mod Pathol 1997;10:182-7.
47. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994;265:2037-48.
48. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999;65:220-8.
49. van der Pol WL, Jansen MD, Sluiter WJ, et al. Evidence for non-random distribution of Fcγ receptor genotype combinations. Immunogenetics 2003;55:240-6.
50. Dosemeci M, Wacholder S, Lubin JH. Does nondifferential misclassification of exposure always bias a true effect toward the null value? Am J Epidemiol 1990;132:746-8.